Investors & Media

Corporate Profile

NGM Bio is focused on discovering and developing novel, life-changing medicines for people whose health and lives have been disrupted by disease. The company’s biology-centric drug discovery approach aims to seamlessly integrate interrogation of complex disease-associated biology and protein engineering expertise to unlock proprietary insights that are leveraged to generate promising product candidates and enable their rapid advancement into proof-of-concept studies. As explorers on the frontier of life-changing science, NGM Bio aspires to operate one of the most productive research and development engines in the biopharmaceutical industry. All therapeutic candidates in the NGM Bio pipeline have been generated by its in-house discovery engine, with a disease-agnostic mindset, always led by biology and motivated by unmet patient need. Today, the company has seven disclosed programs, including four in Phase 2 or 2b studies, across three therapeutic areas: cancer, retinal diseases and liver and metabolic diseases.

Corporate Presentation

Explorer Series 1: NGM Bio’s Discovery Engine

Explorer Series 2: Myeloid Reprogramming and Stromal Checkpoint Programs

Explorer Series 3: NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate

Explorer Series 4: NGM621

CATALINA Topline Results Presentation

NGM Bio Corporate Presentation November 2022

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News & Events

News Releases

December 7, 2022

NGM Bio Presents Preliminary Data from Phase 1 Monotherapy Dose Escalation Trial of NGM707 in Patients with Advanced or Metastatic Solid Tumors at 2022 ESMO-IO Annual Meeting

November 7, 2022

NGM Bio Announces Poster Presentation Featuring Initial Findings from Ph1a Trial of NGM707 in Patients with Advanced Solid Tumors at Upcoming 2022 ESMO-IO Annual Meeting

November 4, 2022

NGM Bio Announces Poster Presentation Featuring Preclinical Characterization of NGM936 at Upcoming 2022 ASH Annual Meeting

Contact Information

investor relations

ir@ngmbio.com

media relations

media@ngmbio.com